Candidozyma auris has earned a reputation as one of the most concerning healthcare-associated fungal pathogens of the modern era. Unlike many of its fungal relatives, it persists stubbornly in the hospital environment, colonizes surfaces and medical equipment, spreads between patients in healthcare facilities, and frequently displays resistance to the antifungal drugs clinicians rely upon most. First recognized as a human pathogen less than two decades ago, it has since been reported on multiple continents, triggering outbreaks in intensive care units and prompting public health agencies to classify it as a serious global health threat. Its ability to survive routine disinfection and to be misidentified by conventional laboratory methods has made containment exceptionally difficult, and each new clinical dataset contributes valuable intelligence about how the organism behaves in actual patient care.

The Turkish research team set out to answer a question that has divided the field: does C. auris candidemia actually kill more patients than candidemia caused by other Candida species, or does it merely appear more lethal because it disproportionately infects patients who are already gravely ill? To address this, the investigators conducted a single-center retrospective cohort study, identifying every adult patient with candidemia seen at their institution and classifying infections by species. Identification was performed using MALDI-TOF mass spectrometry, a rapid proteomic technique that has become the gold standard for distinguishing C. auris from look-alike yeasts that older biochemical panels frequently confuse with it. Accurate speciation matters enormously here, because misidentification has historically hampered both surveillance and appropriate treatment.

The clinical profiles of the two patient groups differed in telling ways. Patients with C. auris candidemia had spent significantly longer in the hospital before their bloodstream infection developed, a pattern consistent with a healthcare-associated pathogen that colonizes patients during extended stays. They also more frequently had central venous catheters, the indwelling lines that provide fungi with a direct portal into the bloodstream, and greater exposure to corticosteroids, which suppress immune defenses. These exposures are classic risk factors for invasive candidiasis in general, but their heightened frequency in the C. auris group underscores how thoroughly this organism is woven into the fabric of modern intensive medical care. The findings reinforce the picture of C. auris as an opportunist that exploits the very devices and drugs that keep critically ill patients alive.

When the researchers examined crude outcomes, the headline number was striking in its symmetry: 30-day all-cause mortality was 62.3 percent among patients with C. auris candidemia and 62.5 percent among those with non-auris Candida infections, a difference of essentially zero. On the surface, this suggests the emerging pathogen is no deadlier than its established cousins. But crude comparisons in observational data can be deeply misleading, and the investigators knew that the patients harboring C. auris arrived at their infections with a different constellation of vulnerabilities. To disentangle the effect of the organism itself from the effect of patient characteristics, they turned to more sophisticated statistical machinery.

The team employed a multivariable Firth-penalized logistic regression model, a technique designed to produce more stable estimates when outcomes are imbalanced or sample sizes are modest, and they handled missing data through multiple imputation. The model was constructed with clinical input to ensure that the variables adjusted for reflected genuine medical knowledge rather than statistical convenience. After adjustment, C. auris candidemia was associated with higher estimated odds of 30-day mortality, with an adjusted odds ratio of 1.967, meaning the odds of death were nearly doubled relative to non-auris candidemia. However, the 95 percent confidence interval ranged from 0.954 to 4.055 and included the null value of one, with a p value of 0.067, meaning the association fell just short of conventional statistical significance.

To translate the regression results into more intuitive risk terms, the researchers used g-computation to estimate standardized marginal mortality risks. Under this approach, the adjusted 30-day mortality was estimated at 69.7 percent for C. auris candidemia compared with 59.3 percent for non-auris Candida candidemia, corresponding to an adjusted risk difference of 10.4 percentage points, with a confidence interval spanning from minus 0.2 to plus 21.3 points. In other words, once patient severity was accounted for, the data hinted that C. auris infections carry a genuinely elevated mortality burden, potentially adding roughly ten deaths per hundred patients, but the uncertainty around that estimate means the true effect could range from negligible to substantial. The authors are explicit that these findings should be interpreted as associative rather than causal, and that larger prospective multicenter studies across diverse healthcare settings are needed to confirm them.

Beyond the comparison between species, the study identified the factors that independently predicted death within 30 days across the entire cohort. Older age, higher scores on the Sequential Organ Failure Assessment, or SOFA, scale, the presence of septic shock, corticosteroid use, and hemodialysis were all associated with higher adjusted odds of mortality. These determinants are familiar from the broader candidemia literature: they reflect the reality that bloodstream fungal infections are most lethal in patients whose organs are already failing and whose immune systems have been blunted by illness or medication. The consistency of these predictors with prior research lends credibility to the study’s methodology and suggests the dataset behaves as expected, strengthening confidence in the species-specific comparisons.

The antifungal susceptibility findings carry important practical implications for treatment. Among C. auris isolates, echinocandin non-wild-type phenotypes were uncommon, which is welcome news because echinocandins are the recommended first-line therapy for invasive candidiasis and are often the drug class of choice against C. auris. However, elevated minimum inhibitory concentrations for amphotericin B were observed in approximately one-third of tested isolates, a troubling signal for an older but still-used antifungal that clinicians may reach for when first-line options fail or are unavailable. Meanwhile, resistance to fluconazole was frequent among tested Candida parapsilosis isolates, a reminder that antifungal resistance is not confined to the emerging pathogen and that susceptibility testing remains essential for guiding therapy across all Candida species. Susceptibility results were interpreted using applicable EUCAST clinical breakpoints or epidemiological cut-off values, and where no interpretive criteria existed, results were reported descriptively, reflecting the ongoing challenge that interpretive standards for some antifungal-organism combinations are still evolving.

The study’s conclusions are measured but consequential. C. auris candidemia, the authors report, is characterized by a distinct profile of healthcare-associated exposures and a distinct antifungal susceptibility pattern, and while crude mortality appears similar to other candidemia, adjusted estimates point toward higher mortality that remains statistically imprecise. For clinicians, the message is twofold: patients colonized or infected with C. auris deserve vigilant attention to modifiable risk factors such as catheter management and careful stewardship of corticosteroids, and treatment decisions should be anchored in susceptibility data rather than assumptions. For public health officials, the findings add to the accumulating evidence that C. auris is not simply another Candida species but a pathogen with its own epidemiology, its own resistance landscape, and potentially its own mortality penalty. As the global footprint of this fungus continues to expand, studies like this one, grounded in real-world clinical data and rigorous statistical adjustment, will be essential for calibrating the response. The research received no specific funding, was approved by the Etlik City Hospital clinical research ethics committee, and was conducted in accordance with the Declaration of Helsinki, with the requirement for informed consent waived given its retrospective design.

Subject of Research: Comparison of clinical characteristics, antifungal susceptibility, and 30-day mortality in Candidozyma auris versus non-auris Candida candidemia

Article Title: Clinical characteristics, treatment strategies, and factors associated with 30-day mortality in Candidozyma auris versus non-auris Candida candidemia: a retrospective cohort study

Article References: Kuzi, S., Çiçek Şentürk, G., Kul, G., Haykır, A., Yılmaz, N., Korkmaz, N., Bulut, D., Aslan, M., Yapar Toros, G., Şencan, İ., & Tütüncü, E. E. (2026). Clinical characteristics, treatment strategies, and factors associated with 30-day mortality in Candidozyma auris versus non-auris Candida candidemia: a retrospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14401-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14401-4

Keywords: Candidozyma auris, candidemia, antifungal resistance, 30-day mortality, bloodstream infection, echinocandins, amphotericin B, fluconazole resistance, septic shock, healthcare-associated infection, MALDI-TOF, risk factors

The study drew on the CandidICU cohort, a retrospective collection of all adults hospitalized between January 1, 2015 and January 1, 2023 in participating intensive care units who had at least one positive blood culture for Candida within seven days before admission or during the stay. Of 492 patients initially enrolled, the investigators narrowed the analytic population to 237 individuals. The exclusions were deliberate and methodologically consequential: 122 patients who died within the first five days were removed because they could never have been eligible for either treatment strategy in the emulated trial, 76 patients treated for more than 21 days were excluded because such prolonged courses usually signal complicated infections such as endocarditis or deep-seated dissemination, 41 patients treated for fewer than five days were dropped because such brief exposure likely reflected discontinuation for unrelated reasons, and 16 patients lacked complete data. What remained was a focused population of patients with uncomplicated candidemia who survived long enough to plausibly receive either a short or a long course.

The population was severely ill. Median age was 62 years, roughly two-thirds were men, and the median SAPS II severity score was 53, a figure that places these patients among the sickest in intensive care. Candida albicans caused about two-thirds of infections, with Candida glabrata the most common non-albicans species, and echinocandins served as initial therapy in more than 84 percent of cases. Notably, patients excluded for early death were markedly sicker than those included, with higher SAPS II scores and greater rates of cirrhosis, renal replacement therapy, and acute respiratory distress syndrome—a comparison that supported the appropriateness of the five-day exclusion while clarifying that the findings apply only to patients who survive the initial phase of infection.

The central methodological challenge in any observational study of treatment duration is that duration is not known at the moment treatment begins. Patients who receive short courses may differ systematically from those treated longer, and clinicians often stop therapy early precisely because a patient is deteriorating, or conversely because the patient is improving rapidly. Worse, so-called immortal time bias arises because a patient must survive long enough to accumulate days of therapy. To confront these distortions, the researchers turned to target trial emulation, a framework in which the analysis is explicitly designed to mimic a randomized trial. The key instrument was a technique called cloning, censoring, and weighting: every patient was duplicated into two virtual clones, one assigned to a short-course strategy and one to a long-course strategy, and each clone was censored at the moment its observed treatment deviated from the assigned strategy, using a 10-day grace period for classification.

On top of the cloning structure, the team applied inverse probability of treatment weighting based on a propensity score model that incorporated 22 baseline covariates, including age, sex, comorbidities such as cirrhosis and diabetes, immunosuppression, neutropenia, mechanical ventilation, the Candida species involved, echinocandin use, and suspected source of infection. The model achieved a C-statistic of 0.704, and weighting brought covariate balance within acceptable limits, reducing the standardized mean difference for Candida albicans status from 0.417 to 0.108. Sensitivity analyses varied the grace period to 7 and 14 days, adjusted for treatment center, and applied inverse probability of censoring weights to address potential informative censoring, all yielding results consistent with the primary analysis.

The raw numbers told a dramatically different story from the adjusted ones. Among the 237 patients, 48 received short-course therapy and 189 received long courses, and crude 90-day mortality was 79.2 percent in the short-course group versus 39.7 percent in the long-course group, a difference so stark it would seem to condemn abbreviated therapy outright. But after cloning and weighting, that apparent chasm collapsed: the weighted hazard ratio for 90-day mortality was 1.14, with a 95 percent confidence interval of 0.82 to 1.58 and a p-value of 0.449—statistically indistinguishable from no effect. The authors argue that the crude difference was almost certainly driven by confounding by indication and selection effects rather than by any causal harm of shorter treatment, and they present the attenuation itself as a cautionary lesson about the magnitude of bias in conventional observational analyses of antimicrobial duration.

Secondary outcomes offered additional nuance. In weighted analyses, patients who received shorter therapy had significantly shorter hospital stays, a median of 31 days versus 46 days, and shorter intensive care unit stays, though the authors urge caution because early death shortens length of stay through competing risk. No meaningful differences emerged in ventilator duration, renal replacement therapy, vasopressor use, ventilator-associated pneumonia, or recurrent fungemia, and no cases of second fungemia occurred in the short-course group. Restricted mean survival time analyses hinted at a possible survival advantage for longer therapy at 30 days, with a p-value of 0.094, but the difference was not significant and faded at later time points.

The authors are emphatic that these findings should not change clinical practice. The confidence interval is wide, compatible with as much as a 58 percent relative increase in mortality from short courses, and the study was never designed as a formal non-inferiority trial. Residual confounding from unmeasured factors—time to blood culture clearance, microbiologic response, adequacy of source control, and the clinical reasons behind a clinician’s decision to stop therapy—cannot be excluded, and the modest residual imbalances in solid tumor status and SAPS II after weighting leave open the possibility of residual bias. With only 48 patients in the short-course group, the study had 69 percent power to detect a 25 percent absolute mortality difference, and the extreme censoring inherent to the cloning design limits the reliability of survival estimates in that arm beyond the grace period.

Nevertheless, the study fills a genuine evidence gap. Two randomized trials comparing 7 versus 14 days of therapy are registered but have not begun enrolling patients, and both exclude the sickest individuals—those in shock or requiring mechanical ventilation—precisely the population this French analysis addresses. From a stewardship perspective, the results are biologically plausible: prolonged antifungal exposure carries risks of hepatotoxicity, drug-drug interactions, and selection of resistant isolates, including echinocandin-resistant strains emerging after relatively brief exposure. The authors suggest that distinguishing uncomplicated from complicated candidemia may help clinicians and antimicrobial stewardship programs weigh abbreviated courses in selected patients who survive the early phase and show clear clinical improvement, while careful screening for ocular, cardiac, and deep-seated complications remains essential before any decision to shorten therapy. Until randomized trials specifically designed for intensive care populations deliver definitive answers, this target trial emulation offers the most rigorous glimpse yet into a question that has governed antifungal prescribing for decades without ever having been properly tested.

Subject of Research: Optimal duration of antifungal therapy for critically ill adults with candidemia in the intensive care unit

Article Title: Association of antifungal treatment duration with 90-day mortality in critically ill adults with candidemia: a multicenter target trial emulation in France

Article References: Reizine, F., Henry, J., Desmedt, L., Camus, C., Tadié, J. M., Coirier, V., Arrive, F., Burban, E., Eustache, G., Belleville, T., Marc, A., Malherbe, J., Bouju, P., Jaubert, P., Lesieur, O., Leclerc, M., Fillâtre, P., Frérou, A., Prével, R., … Gangneux, J.-P. (2026). Association of antifungal treatment duration with 90-day mortality in critically ill adults with candidemia: a multicenter target trial emulation in France. eClinicalMedicine, 99, Article 104178. https://doi.org/10.1016/j.eclinm.2026.104178

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104178

Keywords: candidemia, antifungal therapy duration, intensive care unit, target trial emulation, cloning censoring weighting, 90-day mortality, Candida albicans, echinocandins, antimicrobial stewardship, immortal time bias, propensity score, eClinicalMedicine